Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

991 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells.
Ciceroni C, Arcella A, Mosillo P, Battaglia G, Mastrantoni E, Oliva MA, Carpinelli G, Santoro F, Sale P, Ricci-Vitiani L, De Maria R, Pallini R, Giangaspero F, Nicoletti F, Melchiorri D. Ciceroni C, et al. Among authors: nicoletti f. Neuropharmacology. 2008 Sep;55(4):568-76. doi: 10.1016/j.neuropharm.2008.06.064. Epub 2008 Jul 8. Neuropharmacology. 2008. PMID: 18621067
Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis.
Matrisciano F, Zusso M, Panaccione I, Turriziani B, Caruso A, Iacovelli L, Noviello L, Togna G, Melchiorri D, Debetto P, Tatarelli R, Battaglia G, Nicoletti F, Giusti P, Girardi P. Matrisciano F, et al. Among authors: nicoletti f. Neuropharmacology. 2008 Feb;54(2):428-37. doi: 10.1016/j.neuropharm.2007.10.020. Epub 2007 Nov 7. Neuropharmacology. 2008. PMID: 18082849
Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.
Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, Larocca LM, Pallini R, Traficante A, Spinsanti P, Ricci-Vitiani L, Arcella A, De Maria R, Nicoletti F, Battaglia G, Melchiorri D. Ciceroni C, et al. Among authors: nicoletti f. Cell Death Differ. 2013 Mar;20(3):396-407. doi: 10.1038/cdd.2012.150. Epub 2012 Nov 23. Cell Death Differ. 2013. PMID: 23175182 Free PMC article.
Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors.
Bruno V, Battaglia G, Kingston A, O'Neill MJ, Catania MV, Di Grezia R, Nicoletti F. Bruno V, et al. Among authors: nicoletti f. Neuropharmacology. 1999 Feb;38(2):199-207. doi: 10.1016/s0028-3908(98)00159-2. Neuropharmacology. 1999. PMID: 10218860
991 results